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Introduction. Smoking is the single most important aetiological factor for the development and progression of
atherosclerosis. Unfortunately, most patients receive little or no treatment for their nicotine addiction. This review aims to
make evidence based recommendations for smoking cessation as part of a comprehensive delivery of best medical therapy to
patients with peripheral arterial disease.
Methods. A search of MEDLINE (1966 to 2003) and the Cochrane library was undertaken for studies relating to smoking
cessation. Major priority was given to meta-analyses of randomised controlled trials including Cochrane reviews.
Results. Physician advise, nicotine replacement therapy and Bupropion are all evidence based treatments that have success
in increasing the likelihood of permanent smoking cessation. A basic understanding of the psychology of addictive behaviour
is essential so that appropriate advice and treatment can be tailored to individual patients.
Conclusions. Complete and permanent smoking cessation is by far the most clinically and cost effective intervention in
patients with atherosclerosis. Greater awareness of smoking cessation strategies, by clinicians treating vascular patients, is
essential for the effective delivery of best medical therapy.
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Introduction
So-called ‘best medical therapy’ (BMT) is now widely
accepted as the mainstay of treatment for patients with
peripheral arterial disease (PAD).1,2 Smoking is the
single most important aetiological factor for the
development and progression of atherosclerosis
(Table 1), with other factors such as hyperlipidaemia
contributing a more minor role.3,4 For this reason, it
has been argued that it is clinically and cost-ineffective
to commence patients on anti-platelet and lipid-low-
ering agents if they continue to smoke; although the
authors would not agree with this view, as it is not
evidence-based. Unfortunately, most patients get little
or no treatment for their nicotine addiction and
smoking cessation rates remain depressingly low.5
In this article, we review the literature and make
evidence-based recommendations regarding smoking
cessations strategies as part of a comprehensive
delivery of BMT to PAD patients.
Methods
A search of MEDLINE (1966–2003) and the Cochrane
Library was performed to identify articles relating to
smoking cessation. Search terms included ‘smoking
cessation’, ‘nicotine replacement therapy’ (NRT),
‘Bupropion’ or ‘Zyban’, combined, where possible,
with ‘peripheral vascular/arterial disease’. Cross-
referencing from the reference lists of major relevant
articles identified further papers. The medical litera-
ture is awash with evidence on smoking cessation and
as such, highest priority was given to meta-analyses of
randomised controlled trials including Cochrane reviews.
Nicotine as a drug of addiction
Nicotine ranks alongside heroin and cocaine as one of
the most addictive known substances and cigarettes
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represent the most effective means of delivering of
nicotine to the brain.6 Perhaps not surprising, there-
fore, that although 70% of smokers express a desire to
stop, less than a third attempt to do so and only 2%
succeed each year, most after several failed quit
attempts.7
The trans-theoretical model
Before specifically discussing smoking cessation strat-
egies it is necessary to understand something of the
psychology of addictive behaviour modification.
There are many different paradigms to chose from
but the trans-theoretical model is probably the most
widely used cognitive framework and describes
progression through five stages (Fig. 1).8
Pre-contemplation. The individual has no intention of
changing their behaviour (in this case smoking) in the
foreseeable future and is un-, or under-, aware that
their behaviour (smoking) is the cause of their
problem.
Contemplation. The individual has become aware
that smoking is the problem and has expressed an
intention to stop within 6 months. This most fre-
quently occurs following the diagnosis of a smoking
related problem. In this stage patients weigh up the
pros and cons of smoking cessation and, hopefully,
conclude that they should make a quit attempt at some
point in the future.
Preparation. The individual intends to stop smoking
in the near future (,1 month). People at this stage
have frequently had previous unsuccessful quit
attempts and often make (ineffective) behavioural
modifications such as cutting down the numbers of
cigarettes smoked.
Action. The individual stops smoking and maintains
early abstinence. Significant effort is required and it is
at this point that control of withdrawal symptoms
(Table 2) is so important to success.
Maintenance. This is reached 6 months after success-
ful abstinence and continued efforts are made to
prevent relapse.
Physician advice
A Cochrane Collaboration review of pooled data from
16 trials found a small but significant benefit from brief
physician advice compared to no advice (odds ratio
[OR] 1.69) and suggested that more frequent advice
might be marginally more effective.9 It is essential
therefore, that effective advice (the five As) is delivered
at every possible opportunity (Table 3).10,11 The
primary benefit of cognitive paradigms, such as the
trans-theoretical model, is as an aid to physicians in
understanding that patients at different stages require
different levels and types of support.12 For example, it
is unrealistic to expect ‘pre-contemplators’ to stop
smoking immediately. Instead, the aim should be to
increase their awareness of the problem in the hope of
down-staging them to the ‘contemplation’ stage.
Contemplators require repeated reinforcement and
encouragement to follow through with their inten-
tions. It is particularly important to recognise when
Table 1. The association between smoking and PAD.
At least 80% of PAD patients are current or ex-smokers32,33
Smokers are 16 times more likely to develop PAD than non-smokers4
Smokers develop PAD 10 years earlier than non-smokers34
Continued smoking is associated with:
† disease progression35,36
† increased bypass graft failure rates37 – 39
† a 5-year mortality of around 40–50%33
† a 50% reduction in the chance of surviving for 5 years after
bypass surgery40
Smoking cessation is associated with a rapid reduction in
cardiovascular risk and a slower but sustained reduction in the
risk of both respiratory and non-respiratory cancers41
Fig. 1. The transtheoretical model of intentional behavioural
change as applied to smoking. Figures in brackets represent the
proportion of smokers within the various stages.8
Table 2. Prevalence and duration of nicotine withdrawal symp-
toms.42
Symptom Duration Prevalence (%)
Irritability/aggression ,4 weeks 50
Depression ,4 weeks 60
Restlessness ,4 weeks 60
Poor concentration ,2 weeks 60
Increased appetite .10 weeks 70
Increase in weight (6–8 lbs avg.) Long-term .80
Light-headedness ,48 h 10
Night-time awakenings ,1 week 25
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patients are in the ‘preparation’ stage as it is here that
they are most responsive, and where adjunctive
therapies, such as NRT or bupropion (Zyban), as
well as referral to a specialist clinic, are most effective.
There is no evidence that ‘cutting down’ the numbers
of cigarettes smoked, or smoking brands with a lower
tar or nicotine content, aids the quit attempt.7 Patients
who cut down often subconsciously smoke more
efficiently to compensate for the increased fluctuations
in blood nicotine levels and may, paradoxically,
become more dependent on smoking. Rather, patients
should be encouraged to set a specific date within the
next couple of weeks on which they will stop
completely. Some authorities actually recommend
encouraging clients to ‘over-smoke’ prior to the quit
attempt on the grounds that this will leave the client
remembering the unpleasant effects of smoking such
as agitation and nausea. Home, family, work and
leisure circumstances need to be appropriately modi-
fied prior to the quit date. For example, the quit
attempt is far more likely to be successful if other
smoking members of the household stop at the same
time, and packets of cigarettes and other smoking
equipment (lighters, ashtrays) are discarded. Most
patients require three or four such quit attempts before
finally being successful (abstinence .6 months) and
even beyond this point there are significant relapse
rates.
Assessing cigarette intake
One of the inherent problems with self-reported
cigarette consumption is that it correlates poorly
with blood nicotine levels because it does not take
into account the type of cigarette, depth and frequency
of inhalation, and the completeness with which each
cigarette is smoked.13 An accurate assessment of
cigarette consumption is useful to motivate abstinence
by providing feedback and to verify self-reports of
abstinence.
The most commonly used assessment tool in
smoking cessation clinics is the measurement of
exhaled breath carbon monoxide (CO). CO is
measured in parts per million (ppm). Values of 0–
6 ppm indicate a non-smoker, 7–10 ppm a light-
smoker, 10 – 20 ppm a moderate smoker and
.20 ppm a heavy smoker. Measurement of exhaled
CO is quick and easy to perform in the clinical setting.
However, it has the drawback that CO is not specific to
cigarette smoke and, because CO has a short half life
(3–5 h), the levels relate to the number of cigarettes
smoked that particular day and levels fall to normal
within 24 h of abstinence.
A more sensitive and specific method of quantify-
ing cigarette consumption is the measurement of
cotinine.14 Cotinine is the primary metabolite of
nicotine and can be detected in serum, saliva and
urine. Cotinine has a long half-life (16 h) and, there-
fore, fluctuates less than CO on a day-to-day basis and
can detect smoking over the preceding 3–4 days.
Unlike CO, as cotinine is measured in the laboratory
the results cannot be fed back immediately to the
patient in the clinic. Until near-patient cotinine assays
become commercially available and affordable, its use
will probably be limited as a research tool.
Nicotine replacement therapy
All patients in the preparation stage should be offered
NRT (or Zyban, see below). NRT is used to reduce
nicotine withdrawal symptoms as patients pass from
the preparation into the action stage (Table 2). No
current NRT formulation can match cigarette smoking
in terms of the rate and concentration of nicotine
delivery to the brain (10–20 s) (Fig. 2). Nevertheless, a
Cochrane review of 110 trials has proved beyond
reasonable doubt that NRT, in all its forms, is 1.7–2.3
times more effective than placebo at achieving main-
tained smoking cessation (Fig. 3).15 In the primary care
setting, NRT can be expected to improve quit rates
from 5 to 10% and, in more intensive settings, from 10
to 20%.16 There are limited data on the effectiveness of
NRT in specific subgroups, such as those with
cardiovascular or peripheral vascular disease.17 How-
ever, it is widely agreed that NRT is safe and does not
lead to an excess of cardiovascular events.18 – 20
There is no level I evidence to support the super-
iority of any particular NRT formulation or dose.17
Patches are probably easiest to use while the gum,
nasal spray and inhaler offer more control over the
dose and speed of delivery. The patch is available in
Table 3. Suggested guidelines for physician advice for smoking
cessation (the five As).10,11
Ask At every patient contact episode enquire about current
and past smoking status, previous ‘quit attempts’ and
previous experience with NRT
Advise Strongly advise all smokers to quit. Educate all smokers
about the risks of continued smoking and the benefits of
cessation
Assess Identify the smoker’s current stage in the transtheoretical
model
Assist All patients in the preparation stage should be targeted for
further intervention and offered NRT or bupropion
Arrange Suitable follow-up needs to be arranged and referral to a
smoking cessation clinic needs to be considered
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16-hour and 24-hour preparations and in a variety of
doses; however, there is no proven difference in
efficacy between the two preparations.21 Pragmati-
cally, it is recommended to reserve the 24-hour patch
for those with early morning cravings because it may
lead to insomnia in less dependent smokers. The level
of dependence should determine the dose of the
patch.22 It is applied first thing in the morning and
the manufacturers recommend gradually reducing the
strength of the patch over time. However, research
has shown that stopping the patch abruptly is just as
effective.15,17
Nicotine gum is available in 2 and 4 mg doses, the
latter is recommended for those who smoke more than
20 cigarettes per day. Initially, about 12–15 pieces are
required per day aiming to reduce the amount over a
period of 2–3 months. The gum needs to be chewed
until the taste is strong and then parked between the
cheek and the gum to allow slow absorption via the
buccal mucosa. The tablets and lozenges work in a
similar way to the gum. They are dissolved under the
tongue and nicotine is absorbed via the buccal
membrane. The taste of these preparations often
reduces compliance, however, if it is stressed to the
patients that they are medications and not confec-
tionary the taste quickly becomes tolerated. The
nicotine inhaler resembles a cigarette and is useful
for those who miss the hand-to-mouth movements of
smoking. It is important to appreciate that the nicotine
from the inhaler is absorbed via the buccal membrane
and not via the lungs. The nasal spray is the most
effective and rapidly absorbed of the NRT products, it
Fig. 2. Illustration of the peak plasma nicotine levels obtained with a variety of nicotine delivery systems.43
Fig. 3. Odds ratios of successful smoking cessation with the various forms of nicotine replacement therapy.15
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can, however, cause nasal and throat irritation that is
not tolerated by one in three patients. Although
currently unlicensed, pooled data from five trials
suggest that combination therapy, for example using
the patch continuously with the gum as required,
increases quit rates.15,17 Combination therapy should
be reserved for those who are unsuccessful quitting
with a single type of NRT. The contraindications and
side effects of NRT are highlighted in Table 4.
Bupropion
Nicotine stimulates dopaminergic pathways in the
mesolimbic system, an area of the brain associated
with dependence on other psychoactive drugs. Bupro-
pion inhibits the re-uptake of both noradrenaline and
dopamine and it is probably this activity in the
mesolimbic system, rather than its anti-depressant
effects, that accounts for its utility as an aid to smoking
cessation.23,24 A meta-analysis of 10 placebo-con-
trolled, double-blind, randomised controlled trials
involving almost 4000 patients has shown that
bupropion results in significantly higher abstinence
rates (OR 2.16).17 One of two studies directly compar-
ing NRT with bupropion showed the latter to be more
effective, and a single study has shown a combination
of bupropion and NRT to be more effective than
bupropion alone.25 Smokers in the preparation stage
should take 150 mg bupropion daily for 6 days and
then increase to 150 mg twice daily. The quit attempt is
delayed for a further 1–2 weeks to allow time for the
drug to work maximally and the prescription con-
tinued for a further 6 weeks. Patients have to be well
motivated and drug therapy should be combined with
strong support and encouragement. Bupropion is
associated with more side effects than NRT. Specifi-
cally seizures occur in 1 in 1000 patients and therefore
bupropion is contraindicated in patients with any
history of a seizure (Table 4).
Specialist smoking clinics
Specialist smoking clinics offer multi-session pro-
grammes that combine behavioural support with
NRT/Bupropion. Specialist clinics report higher main-
tained cessation rates compared to brief interventions.
It may be argued that this is a result of increased
motivation among patients who attend such clinics,
however, these patients also tend to be more highly
dependent.26 Nonetheless, national guidelines rec-
ommended that all patients should be offered referral
to a smoking cessation clinic27 although it is appreci-
ated that the majority of smokers will not wish to
receive specialist help.26 These clinics should be
centrally based in health districts since it is unlikely
that sufficient demand could be generated in single
primary care practices to make local clinics cost-
effective.26
Other interventions
Evidence exists to show that acupuncture, acupres-
sure, hypnotherapy, aversive smoking and anti-
depressants are ineffective.28 – 31 However, some of
this evidence is based on small trials and further
research in some areas, for example hypnotherapy, is
probably warranted.
Table 4. Contraindications and side effects of bupropion and nicotine replacement products.
Contraindications Side effects
Bupropion History of seizures Dry mouth
Eating disorder Insomnia
CNS tumour Seizures (1:1000)
Acute alcohol or benzodiazepine withdrawal
NRT Transdermal patch Localised skin rash
Insomnia (24 h patch)
Gum Throat irritation
Indigestion
Tablet/Lozenge Severe cardiovascular disease As for gum
Recent myocardial infarction Aphthous ulceration
Recent cerebrovascular event
Inhaler As for gum
Cough
Dry mouth
Nasal spray As for gum
Nasal irritation
Epistaxis
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Summary
Complete and permanent cessation of smoking is by
far the most clinically and cost-effective intervention in
patients with atherosclerosis, including PAD:
(NRT/Zyban ,£2000 per Life Year Gained [LYG];
statins £13,000 per LYG22). Yet, many health care
professionals, even those dealing on a daily basis with
‘vascular’ patients are ignorant of the principles and
practice of smoking cessation strategies and quit rates
remain unacceptably low. This almost certainly reflects
the time and resource consuming nature of cessation
counselling.
Each time a patient is assessed, their current
smoking status and ‘stage’ needs to be actively
identified and recorded. Patients within different
stages require different levels of support, and advice
must be tailored with this in mind. The initial aim is to
provide repeated advice to ‘down stage’ patients into
the preparation stage. Once there, patients can be
targeted for more intensive treatments. NRT and
bupropion are evidence-based therapies and need to
be discussed in relation to a ‘quit date’ with every
patient who has entered the preparation stage. Early
relapse is common and smokers, just like other ‘drug
addicts’, need continuing (life-long) support to deal
with their craving and maintain abstinence.
References
1 Burns P, Gough S, Bradbury AW. Management of peripheral
arterial disease in primary care. Br Med J 2003; 326: 584–588.
2 Burns PJ, Lima E, Bradbury AW. What constitutes best medical
therapy for peripheral arterial disease? Eur J Vasc Endovasc Surg
2002; 24: 6–12.
3 Kannel WB, Shurtleff D. The Framingham study. Cigarettes
and the development of intermittent claudication. Geriatrics 1973;
28(2): 61–68.
4 Cole CW, Hill GB, Farzad E, Bouchard A, Moher D, Rody K
et al. Cigarette smoking and peripheral arterial occlusive disease.
Surgery 1993; 114: 753–757.
5 Burns PJ, Lima E, Bradbury AW. Second best medical therapy.
Eur J Vasc Endovasc Surg 2002; 24: 400–404.
6 Tobacco Advisory Group, Royal College of Physicians, Nicotine
Addiction in Britain. London: Royal College of Physicians, 2000.
7 Moxham J. Nicotine addiction. Br Med J 2000; 320: 391–392.
8 Prochaska JO, DiClemente CC, Norcross JC. In search of how
people change: applications to addictive behaviours. Am Psychol
1992; 47: 1102–1114.
9 Silagy C, Stead LF. Physician advice for smoking cessation
(Cochrane Review). The Cochrane Library, Oxford: Update
Software, 2002. Issue 4.
10 Anderson JE, Jorenby DE, Scott WJ, Fiore MC. Treating
tobacco use and dependence: an evidence-based clinical practice
guideline for tobacco cessation. Chest 2002; 121(3): 932–941.
11 Karnath B. Smoking cessation. Am J Med 2002; 112: 399–405.
12 Cote M. Vascular nurse as a smoking cessation specialist. J Vasc
Nurs 2000; 18: 47–53.
13 Idle JR. Titrating exposure to tobacco smoke using cotinine—a
minefield of misunderstanding. J Clin Epidemiol 1990; 43:
313–317.
14 Jarvis MJ, Tunstall-Pedoe H, Feyerabend C, Vesey C,
Saloojee Y. Comparison of tests used to distinguish smokers
from non-smokers. Am J Public Health 1987; 77: 1435–1438.
15 Silagy C, Lancaster T, Stead L, Mant D, Fowler G. Nicotine
replacement therapy for smoking cessation (Cochrane Review).
The Cochrane Library, Oxford: Update Software, 2002. Issue 4.
16 Raw M, McNeill A, West R. Smoking cessation guidelines for
health professionals. Thorax 1998; 53(Suppl. 5): S1–S19.
17 NICE, A rapid and systematic review of the clinical and cost
effectiveness of bupropion SR and nicotine replacement therapy
(NRT) for smoking cessation. Technology Appraisal Guidance
No. 39, National Institute for Clinical Excellence, 2002. http://
www.nice.org.uk [Accessed: 16-2-2003].
18 McRobbie H, Hajek P. Nicotine replacement therapy in patients
with cardiovascular disease: guidelines for health professionals.
Addiction 2001; 96: 1547–1551.
19 Joseph AM, Norman SM, Ferry LH, Prochazka AV, Westman
EC, Steele BG et al. The safety of transdermal nicotine as an aid
to smoking cessation in patients with cardiac disease. N Engl J
Med 1996; 335: 1792–1798.
20 Working Group for the Study of Transdermal Nicotine in Patients
with Coronary Artery Disease, Nicotine replacement therapy for
patients with coronary artery disease. Arch Intern Med 1994; 154:
989–995.
21 Daughton DM, Heatley SA, Prendergast JJ, Causey D,
Knowles M, Rolf CN et al. Effect of transdermal nicotine
delivery as an adjunct to low-intervention smoking cessation
therapy. A randomized, placebo-controlled, double-blind study.
Arch Intern Med 1991; 151(4): 749–752.
22 NICE, Guidance on the use of nicotine replacement therapy
(NRT) and bupropion for smoking cessation. Technology
Appraisal Guidance No. 39, National Institute for Clinical
Excellence, 2002. http://www.nice.org.uk [Accessed, 16-2-2002].
23 Holm KJ, Spencer CM. Bupropion: a review of its use in the
management of smoking cessation. Drugs 2000; 59(4): 1007–1024.
24 Peters MJ, Morgan LC. The pharmacotherapy of smoking
cessation. Med J Aust 2002; 176: 486–490.
25 Jorenby DE, Leischow SJ, Nides MA, Rennard SI, Johnston
JA, Hughes AR et al. A controlled trial of sustained-release
bupropion, a nicotine patch, or both for smoking cessation. N
Engl J Med 1999; 340: 685–691.
26 Hajek P, West R. Treating nicotine dependence: the case for
specialist smoker’s clinics. Addiction 1998; 93(5): 637–640.
27 West R, McNeill A, Raw M. Smoking cessation guidelines for
health professionals: an update. Thorax 2000; 55: 987–999.
28 White AR, Rampes H, Ernst E. Acupuncture for smoking
cessation (Cochrane Review). The Cochrane Library, Oxford:
Update Software, 2002. Issue 4.
29 Abbot NC, Stead LF, White AR, Barnes J. Hypnotherpay for
smoking cessation (Cochrane Review). The Cochrane Library,
Oxford: Update Software, 2002. Issue 4.
30 Hajek P, Stead LF. Aversive smoking for smoking cessation
(Cochrane review). The Cochrane Library. Oxford: Update Soft-
ware, 2002. Issue 4.
31 Hughes JR, Stead LF, Lancaster T. Antidepressants for
smoking cessation (Cochrane review). The Cochrane Library.
Oxford: Update Software, 2002. Issue 4.
32 Fowkes FGR, Housley E, Riemersma RA, Macintyre CCA,
Cawood EHH, Prescott RJ et al. Smoking, lipids, glucose
intolerance, and blood pressure as risk factors for peripheral
atherosclerosis compared with ischaemic heart disease in the
Edinburgh artery study. Am J Epidemiol 1992; 135: 331–340.
33 Hirsch AT, Treat-Jacobson D, Lando HA, Hatsukami DK. The
role of tobacco cessation, antiplatelet and lipid-lowering thera-
pies in the treatment of peripheral arterial disease. Vasc Med 1997;
2: 243–251.
34 Lassila R, Lepantalo M. Cigarette smoking and the outcome
after lower limb arterial surgery. Acta Chirurgica Scand 1988; 154:
635–640.
S. D. Hobbs and A. W. Bradbury346
Eur J Vasc Endovasc Surg Vol 26, October 2003
35 Jonason T, Bergstrom R. Cessation of smoking in patients with
intermittent claudication. Acta Med Scand 1987; 221: 253–260.
36 Gardner AW. The effect of cigarette smoking on exercise
capacity in patients with intermittent claudication. Vasc Med
1996; 1: 181–186.
37 Stonebridge PA, Bradbury AW, Murie JA. Continued smoking
and the results of vascular reconstruction. Br J Surg 1994; 81:
51–52.
38 Wiseman S, Powell J, Greenhalgh R, McCollum C, Kench-
ington G, Alexander C et al. The influence of smoking and
plasma factors on prosthetic graft patency. Eur J Vasc Surg 1990; 4:
57–61.
39 Carty CS, Huribal M, Marsan BU, Ricotta JJ, Dryjski M.
Nicotine and its metabolite cotinine are mitogenic for human
vascular smooth muscle cells. J Vasc Surg 1997; 25: 682–688.
40 Faulkner KW, House AK, Castleden WM. The effect of
cessation of smoking on the accumulative survival rates of
patients with symptomatic peripheral vascular disease. Med J
Aust 1983; 1: 217–219.
41 Samet JM. The health benefits of smoking cessation. Med Clin N
Am 1992; 76: 399–414.
42 West RJ. Acute effects of stopping smoking. http://www.rjwest.
co.uk [Accessed, 18-03-2003].
43 Russell MAH. Nicotine intake and its regulation by smokers. In:
Martin WR, Loon GRV, Iwamoto ET, Davis L, eds. Tobacco
Smoking and Nicotine: A Neurobiological Approach. New York:
Plenum Publishing Corporation, 1987: 25–50.
Accepted 23 June 2003
Smoking Cessation Interventions 347
Eur J Vasc Endovasc Surg Vol 26, October 2003
